Newsletters

Issue 34 - May 2022 - Part 1
May 2022 - Part 2

Part 1

• New antimicrobial prescribing guidance
• Ranitidine – licence suspended
• COPD training sessions
• Saxenda® (Liraglutide 6mg/ml Injection) – not for primary care prescribing
• South East Lipid Management Webinar
• Polypharmacy: Understanding the data webinar (24 May)
• Prescribing Midazolam for end of life care
• Local area updates – east Kent

Part 2

• Chlordiazepoxide Librium warning
• The Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update, Pregabalin, Denosumab

Issue 35 - June 2022 - Part 1
June 2022 - Part 2
June 2022 - Part 3

Part 1

• Kent and Medway Position Statement and Risk Mitigation Principles for Anticoagulant prescribing
• FAO GPs and Community Pharmacists: Intelligence Update Report from Sussex Police
• June Shortage article
• Sim 4 Mental Health

Part 2

• The carbon footprint of inhalers
• Reminder: Deadline for Practices to submit returns for MOS 2021/22
• We would like to hear from YOU!

Part 3

• Opportunity to Input into Review of UTI Diagnostic Flowchart
• Information for all General Practitioner and Independent Prescriber colleagues from Maidstone and Tunbridge Wells NHS Trust
• Kent & Medway CCG Medicines Optimisation Team NICE News Bimonthly - June 2022
• FAO Community Pharmacy and GP Dispensing Practices
• Kent and Medway Medicines Optimisation Scheme for 2022-2024

Issue 36 - July 2022 - Part 1
July 2022 - Part 2

Part 1

• Medicines Optimisation System Working at its best – NHS Kent and Medway AND Kent Community Health Foundation Trust (KCHFT) Pharmacy Teams shortlisted for HSJ Patient Safety Awards 2022!
• Good Practice News
• Shortages Summary July 2022
• NICE guidance for Acute Otitis Media
• New NICE guideline: Medicines associated with dependence or withdrawal symptoms (useful for the dependence forming medicines project in the MOS!)
• A reminder for primary care prescribers – Hypomagnesaemia associated with Proton Pump Inhibitors (PPIs)
• Reminder of Potassium Permanganate CAS Alert[1]Inadvertent Oral Administration of Potassium Permanganate
• Asthma and Nebulisers
• Dapagliflozin for treating Chronic Kidney Disease (CKD)
• Kent and Medway Managing Deterioration Management tool – RESTORE2
• Best Practice Guidance for Care Homes

Part 2

• MHRA Drug Safety Update June 2022
• Sentinel Plus Project

• Guidance for Multicompartmental Aids MCAs/Dosette Boxes
• Shortages Summary August 2022
• National Patient Safety Alert: Mexiletine
• MHRA Drug Safety Update
• MHRA Class 4 Medicines Defect Information: Novo Nordisk Limited, NovoRapid® FlexTouch® 100 units/ml, Saxenda® FlexTouch® (liraglutide) 6mg/ml, EL(22)A/33
• CPD conference on Controlled Drugs: Ensuring the Safer Management
• Important Product Supply Information: Shortec Oral Solution
• NICE News Bimonthly - August 2022
• Cow’s Milk Allergy Feed
• Tobacco Industry Lobbying

• Clozapine Safety
• Product Discontinuation: Seroxat (paroxetine hydrochloride) 20mg/10ml oral suspension
• Product Discontinuation: Insuman Infusat 100units/ml solution for injection 3.15ml cartridges (Sanofi) 5 cartridge
• Amoxicillin Prescribing and Duration
• Reminder: Best Practice Guidance for Care Homes
• Medicines Optimisation MHRA Drug Safety Update – August 2022 (for September 2022 MO Newsletter)
• Shortages Summary September 2022
• Medicine Supply Notification – Temazepam 10mg and 20mg tablets – and Local Recommendations
• MHRA – Class 4 Medicines Defect Information: Rosuvastatin 5 mg, 10 mg and 20 mg film-coated tablets EL (22)A/35
• MHRA – Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Ltd, Atorvastatin 4mg/ml Oral Suspension & Sildenafil 10mg/ml Oral Suspension, EL (22)A/39
• MHRA – Class 2 Medicines Recall: Dysport 500 Units Powder for Solution for Injection, EL (22)A/36
• MHRA – Class 2 Medicines Recall: Novartis Pharmaceuticals UK, Sandimmum Oral Soultion, EL (22)A/40

• Guidance on NHS patients who wish to pay for additional private care
• Colchicine Prescribing
• Kent and Medway Position Statement and Risk Mitigation Principles for Anticoagulant Prescribing
• Ardens Long Term Conditions training Webinar
• Medicines Optimisation MHRA Drug Safety Update – September 2022 (for October 2022 MO Newsletter)
• Shortages Summary September 2022
• Medicine Supply Notifications: Nafarelin, Dulaglutide, Semaglutide and Dioralyte
• NICE News
• Asthma Inhalers and the Environment Patient Decision Aid (NG80)
• MHRA Anti-epileptic drugs: Advice on switching between manufacturer’s products.
• World Anti-Microbial Awareness Week (WAAW)
• Revised SPC: Forxiga (Dapagliflozin) film coated tablets
• PrescQipp Award Success
• CPCS request for Support from practices
• Pharmacy Technician Day- 18th October 2022

• Reminder on the Prescribing of Sodium Valproate safely in Women and Girls
• Notification of product name change: Carefine Insulin Pen Needles to Greenfine Insulin Pen Needles
• SPS Medicines Advice Service Information
• Medicines Optimisation MHRA Drug Safety Update – Oct 2022
• Direct oral anticoagulants (DOAC) infographic
• Product Discontinuation: FreeStyle Libre 1
• November Shortages
• Serious Shortage Protocols: Estraderm MX® 50mcg and 75mcg patches
• Discontinuation of Stemetil 5mg/5ml Syrup
• MHRA Class 4 Medicines Defect Information: Venlafaxine XL 300 mg prolonged-release tablets

• HSJ Awards Success
• OTC prescribing
• COPD inhaler guidance reminder
• Discontinuation of Stemetil 5mg/5ml Syrup
• Asthma and nebulisers
• All Ranitidine products – license suspended
• Shortages Summary December 2022
• MHRA Updates
• NICE News December 2022
  

• Safety considerations with Metolazone preparations
• Over the counter medicines resources
• IT Support Ardens / EMIS
• MHRA Drug Safety Update
• Class 4 Medicines Defect Information: Galderma (U.K.) Limited, Epiduo 0.1% / 2.5% gel (45 g)
• Class 4 Medicines Defect Information: Albireo AB, Bylvay 1200 micrograms Hard Capsules, EL (23)A/01 Class 2 MHRA Recall – Dioctyl 100mg capsules
• Shortages
• Medicines Supply Notifications
• Serious Shortage Protocols

• Best Practice Guidance for Care homes
• Ozempic prescribing
• Urgent Field Safety Notice: FreeStyle LibreLink App for Android and FreeStyle Libre 3 App for Android (all versions)
• Celebrating Advanced Practice Conference 17th March 2023
• Shortages
• Medicines Supply Notification: Senokot® syrup and Senokot® 12 Years Plus syrup (both containing 7.5mg/5ml sennosides)
• NICE news February 2023
  

• Launch of the Kent and Medway ICB Medicines Optimisation Webpage
• Dexcom ONE transmitters on EMIS formulary
• Group A Strep (GAS) guidance update and impact on MOS sore throat audit.
• Inhaler Spacer Device Prescribing
• Salbutamol Prescribing
• MDI to DPI Switch
• MHRA Metolazone Drug Safety Update
• Clinical Fellow Scheme Application Information
• NICE CG181 Update
• KMPT Video Guides for Patients on Medicines Information
• Medicines Optimisation MHRA Drug Safety Update – Jan and Feb 2023
• MHRA Class 4 Defect Information- Venlafaxine 150mg,225mg and 300mg
• Shortages Summary March 2023
  

• Hormone Replacement Therapy (HRT) Prepayment Certificate (PPC)
• Chronic Pain Resources
• Non-Medical Prescribing and Controlled Drugs
• Reminder on Oral Hygiene Prescribing
• Antimicrobial Prescribing Survey
• Genomics Webinar: Aminoglycosides Pharmacogenetic Testing
• West Kent PCN Pharmacy Support Network Learning Session
• Medicines Optimisation MHRA Drug Safety Update – March 2023
• NICE News April 2023
• Shortages Summary April 2023
• MHRA - Class 4 Medicines Defect Information: Sandoz Limited, Co-amoxiclav 125/31.25mg/5ml, 250/62.5mg/5ml powder for oral suspension, EL (23)A/14